<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36516010</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2160-7648</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Clinical pharmacology in drug development</Title><ISOAbbreviation>Clin Pharmacol Drug Dev</ISOAbbreviation></Journal><ArticleTitle>First-in-Human Studies of Pharmacokinetics and Safety of Utreloxastat (PTC857), a Novel 15-Lipooxygenase Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>141</StartPage><EndPage>151</EndPage><MedlinePgn>141-151</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpdd.1203</ELocationID><Abstract><AbstractText>Utreloxastat (PTC857) is a 15-lipoxygenase inhibitor being developed to treat amyotrophic lateral sclerosis. This first-in-human study investigated the safety and pharmacokinetics of utreloxastat in healthy volunteers (N&#xa0;=&#xa0;82) in a double-blind, placebo-controlled trial. The effects of a single ascending dose (100-1000&#xa0;mg), multiple ascending doses (150-500&#xa0;mg), and food (500&#xa0;mg) on the pharmacokinetics and safety of utreloxastat were evaluated. Following single doses, the time to maximum plasma concentration (C<sub>max</sub> ) was observed &#x2248;4&#xa0;hours after dosing and the terminal half-life ranged from 20 to 25.3&#xa0;hours. The C<sub>max</sub> and area under the concentration-time curve (AUC) increased slightly over dose proportionally. Following multiple doses (once daily/twice daily), the apparent clearance reduced and terminal half-life was &#x2265;33&#xa0;hours. There was no apparent difference of exposure following morning or evening doses. Varying diets increased the C<sub>max</sub> and AUCs of utreloxastat but did not alter time to C<sub>max</sub> . There were no gender-based differences in exposure. Utreloxastat showed no marked safety signal following single doses up to 1000&#xa0;mg and multiple doses over 14&#xa0;days of 500&#xa0;mg once daily or 250&#xa0;mg twice daily. The results support further development of utreloxastat for the treatment of patients with amyotrophic lateral sclerosis at a 250-mg twice-daily dose administered with food.</AbstractText><CopyrightInformation>&#xa9; 2022 PTC Therapeutics. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Lan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>PTC Therapeutics, Inc., South Plainfield, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giannousis</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>PTC Therapeutics, Inc., South Plainfield, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thoolen</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>PTC Therapeutics, Inc., South Plainfield, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaushik</LastName><ForeName>Diksha</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>PTC Therapeutics, Inc., South Plainfield, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latham</LastName><ForeName>Joey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>PTC Therapeutics, Inc., South Plainfield, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tansy</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>PTC Therapeutics, Inc., South Plainfield, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Jiyuan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>PTC Therapeutics, Inc., South Plainfield, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnston</LastName><ForeName>Mayzie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>PTC Therapeutics, Inc., South Plainfield, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dali</LastName><ForeName>Mandar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>PTC Therapeutics, Inc., South Plainfield, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golden</LastName><ForeName>Lee</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>PTC Therapeutics, Inc., South Plainfield, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>PTC Therapeutics, Inc., South Plainfield, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>PTC Therapeutics, Inc., South Plainfield, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trimmer</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>PTC Therapeutics, Inc., South Plainfield, New Jersey, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Pharmacol Drug Dev</MedlineTA><NlmUniqueID>101572899</NlmUniqueID><ISSNLinking>2160-763X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">15-lipooxygenase inhibitor</Keyword><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">pharmacokinetic</Keyword><Keyword MajorTopicYN="N">utreloxastat (PTC857)</Keyword></KeywordList><CoiStatement>This study is funded by PTC Therapeutics, Inc. All authors are employees and stock owners of PTC Therapeutics, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>14</Day><Hour>12</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36516010</ArticleId><ArticleId IdType="pmc">PMC10107758</ArticleId><ArticleId IdType="doi">10.1002/cpdd.1203</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et&#xa0;al. Amyotrophic lateral sclerosis. Lancet (London, England). 2011;377(9769):942&#x2010;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H, Yang E. Oxidative stress as a therapeutic target in amyotrophic lateral sclerosis: opportunities and limitations. Diagnostics. 2021;11(1546).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8465946</ArticleId><ArticleId IdType="pubmed">34573888</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbott EO, Malek AM, Lacomis D. The epidemiology of amyotrophic lateral sclerosis. In: Handbook of Clinical Neurology. 3rd ed.: Elsevier; 2016:225&#x2010;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">27637961</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. are we any closer to registering a new treatment? Front Aging Neurosci. 2017;9:68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewerenz J, Ates G, Methner A, Conrad M, Maher P. Oxytosis/Ferroptosis&#x2014;(Re&#x2010;) emerging roles for oxidative stress&#x2010;dependent non&#x2010;apoptotic cell death in diseases of the central nervous system. Front Neurosci. 2018;12:214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5920049</ArticleId><ArticleId IdType="pubmed">29731704</ArticleId></ArticleIdList></Reference><Reference><Citation>Snodgrass RG, Br&#xfc;ne B. Regulation and Functions of 15&#x2010;Lipoxygenases in Human Macrophages. Front Pharmacol. 2019;10(719).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6620526</ArticleId><ArticleId IdType="pubmed">31333453</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel SE, Tyurina YY, Zhao J, et&#xa0;al. PEBP1 wardens ferroptosis by enabling lipoxygenase generation of lipid death signals. Cell. 2017;171(3):628&#x2010;641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5683852</ArticleId><ArticleId IdType="pubmed">29053969</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye L, Stockwell B. Transforming lipoxygenases: PE&#x2010;specific enzymes in disguise. Cell. 2017;171:501&#x2010;502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5960801</ArticleId><ArticleId IdType="pubmed">29053966</ArticleId></ArticleIdList></Reference><Reference><Citation>Masaldan S, Bush AI, Devos D, Rolland AS, Moreau C. Striking while the iron is hot: iron metabolism and ferroptosis in neurodegeneration. Free Radical Biol Med. 2019;133:221&#x2010;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">30266679</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogdanov M, Brown RH, Matson W, et&#xa0;al. Increased oxidative damage to DNA in ALS patients. Free Radical Biol Med. 2000;29(7):652&#x2010;658.</Citation><ArticleIdList><ArticleId IdType="pubmed">11033417</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihara Y, Nobukuni K, Takata H, Hayabara T. Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Zn&#x2010;superoxide dismutase mutation. Neurol Res. 2005;27(1):105&#x2010;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">15829169</ArticleId></ArticleIdList></Reference><Reference><Citation>Perluigi M, Fai Poon H, Hensley K, et&#xa0;al. Proteomic analysis of 4&#x2010;hydroxy&#x2010;2&#x2010;nonenal&#x2010;modified proteins in G93A&#x2010;SOD1 transgenic mice&#x2013;a model of familial amyotrophic lateral sclerosis. Free Radical Biol Med. 2005;38(7):960&#x2010;968.</Citation><ArticleIdList><ArticleId IdType="pubmed">15749392</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Santella RM, Liu X, et&#xa0;al. Oxidative stress biomarkers in sporadic ALS. Amyotrophic Lateral Sclerosis. 2008;9(3):177&#x2010;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4332387</ArticleId><ArticleId IdType="pubmed">18574762</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA . Guidance for Industry: Assessing the Effects of Food on Drugs in INDs and NDAs &#x2014; Clinical Pharmacology Considerations. In: 2022.</Citation></Reference><Reference><Citation>Hummel J, McKendrick S, Brindley C, French R. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat. 2009;8(1):38&#x2010;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">18386766</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>